You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
透視港股通丨小米交投活躍,遭淨賣出6.9億

北水總結

4月28日港股市場,北水淨流入8.66億,其中港股通(滬)淨流出2.83億港元,港股通(深)淨流入11.49億港元。

北水淨買入最多的個股是港交所(00388)、藥明生物(02269)、舜宇光學(02382)。北水淨賣出最多的個股是小米集團-W(01810)、騰訊(00700)、中國移動(00941)。

數據來源:盈立智投APP

十大成交活躍股

數據來源:盈立智投APP

個股點評

勞動節假期期間滬深港通交易安排發佈,南向港股通將於4月29日(星期四)至5月5日(星期三)暫停交易;北向滬股通和深股通則於5月3日(星期一)至5月5日(星期三)暫停交易。5月6日(星期四),滬深港通將如常開通。

港交所(00388)獲淨買入6.64億港元。消息面上,香港交易所午間公佈首季業績,期內營收59.6億港元,同比增長49%;股東應佔溢利38.4億元創季度新高,同比升69.76%;一季度平均每日成交金額創季度新高達2244億港元,同比增加86%,環比增加59%;期內滬深港通北向及南向交易量龐大,平均每日成交金額分別創人民幣1,268億元及608億元的季度新高;期內共有32只新股上市,集資額達1366億港元,同比增超9倍。

藥明生物(02269)獲淨買入5.54億港元。消息面上,藥明生物主要股東以每股107港元的價格配售1.08億股股份,套現115.56億港元。大和發佈研究報告,公司主要股東配股減持,相信是受到VC及PE基金所推動,因很多VC及PE基金曾參與了2015年藥明康德(02359)的私有化計劃。該行對藥明生物的未來增長趨勢仍然樂觀,重申藥明生物“買入”評級,目標價140港元。

中國電信(00728)獲淨買入1.88億港元。消息面上,中國電信午間發佈公告,2021年一季度,公司經營收入1068.73億元人民幣,同比增長12.7%;股東應佔利潤64.41億元,同比增長10.6%。5G套餐用戶達到約1.11億戶,滲透率達到31.2%;移動用戶數達到約3.56億戶,淨增523萬戶。

心動公司(02400)獲淨買入1.83億港元。消息面上,新時代證券發佈研報稱,看好心動公司在經多年運營經驗沉澱後的研發能力以及與 TapTap 社區形成的渠道聯動,預計公司 2021 年-2023 年淨利潤分別爲 0.04/1.34/4.32 億元,同比變化-55.6%/3250.0%/222.4%,首次覆蓋給予“強烈推薦”評級。

美團-W(03690)獲淨買入1.48億港元。消息面上,大摩發表報告表示,美團被立案調查不會令市場感到意外。鑑於阿裏巴巴-SW(09988)被調查的先例,預計市監局今次對美團的調查時間將較短,而調查結果將消除市場對美團主要懸而未決的不明朗因素,維持對美團“增持”投資評級及目標價420港元。

復星醫藥(02196)獲淨買入7122萬港元。消息面上,復星醫藥近日公佈2021年第一季度業績,營業收入約人民幣80.56億元,同比增長37%;歸屬於上市公司股東的淨利潤約8.47億元,同比增長46.78%。此外,中信建投發佈研報稱,全球疫情反彈,印度瀕臨失控,管控難度大、未來仍將持續。繼續強調新冠疫苗產業鏈投資機會的挖掘。重視新冠疫苗商業化主線,積極關注受益公司。

小米集團-W(01810)遭淨賣出6.97億港元。消息面上,瑞銀髮表報告稱,印度銷售方面,預計小米的智能手機銷量在今明兩年將分別達到4000萬和4500萬部,同比增長7%和13%。如果Jio-Google手機市場反應成功,小米在4G市場的低端市場會損失一些份額,並估計印度市場佔小米收入的15%至20%,給予小米“中性”評級,目標價28元。此外有媒體報道,OPPO集團已在籌備造車事項。與小米一樣,OPPO造車計劃的推動者也是創始人陳明永。

此外,舜宇光學(02382)、安踏體育(02020)、錦欣生殖(01951)分別獲淨買入2.56億、2.37億、1.71億港元。而騰訊(00700)、中國移動(00941)、中芯國際(00981)分別遭淨賣出4.78億、1.92億、1639萬港元。

當日港股通淨買入和淨賣出排行榜

(港股通持股比例排行,交易所數據T+2日結

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account